Overview

Dupilumab Effects Against Aeroallergen Challenge

Status:
Not yet recruiting
Trial end date:
2027-11-01
Target enrollment:
Participant gender:
Summary
The trial involves two interventions: (i) exposure to HDM in the ACC and (ii) administration of dupilumab/placebo for dupilumab.
Phase:
Phase 2
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio
Collaborators:
National Institute of Allergy and Infectious Diseases (NIAID)
Regeneron Pharmaceuticals
Treatments:
Antibodies, Monoclonal